Be Clinical, a skincare brand, has raised ₹2 crore in a seed funding round led by Titan Capital, with participation from P-TAL founder Aditya Agarwal.
The seed fund raised will be used to bring manufacturing in-house to improve quality control, protect its formulations, and expand into new anti-ageing categories, including preventive and corrective skincare.
Founded in May 2025 by Hemangi Dhir, Be Clinical focuses on clinically validated, medical-grade formulations that target early signs of ageing, with a particular appeal to Indian Gen Z and Millennial consumers.
Be Clinical offers medical-grade, efficacious formulations designed to protect, correct, and optimise skin health at every life stage. The startup operates through a direct-to-consumer model, blends nature-based ingredients with dermatological science.
“Securing this investment is a strong validation of our vision. Anti-ageing has often been treated as an afterthought in skincare, but at Be Clinical, it’s our primary focus. We’re building a brand that addresses a real and growing need-especially among Indian Gen Z and Millennial consumers, who are now seeking targeted, effective solutions earlier in their skincare journey. I feel incredibly optimistic about the future and confident that Be Clinical will set a new standard for science-first, results-driven skincare in India,” said Hemangi Dhir, Founder of Be Clinical.
“We invested in Be Clinical because it sits at the intersection of science and self-care. What truly stood out was the founder’s deep understanding of the modern skincare consumer, not just what they buy, but why. Be Clinical is not just building products. It is building long-term trust in a category ripe for disruption,” said a spokesperson for Titan Capital.
